Table 2.

SARS-CoV-2 laboratory testing in 21 individuals with MIS-C who had received a COVID-19 vaccine

		Total	Onset after first dose of COVID-19 vaccine	Onset after second dose of COVID-19 vaccine
MIS-C		21	11 (52%)	10 (48%)
With evidence of SARS-CoV-2 infection		15	10 (67%)	5 (33%)
	Positive NAAT (past or recent)*	10	5 (50%)	5 (50%)
	Negative NAAT and positive anti-nucleocapsid antibody test	5	4 (80%)	1 (20%)
Without evidence of SARS-CoV-2 infection†		6	1 (17%)	5 (83%)

Data are n or n (%). MIS-C=multisystem inflammatory syndrome in children. NAAT=nucleic acid amplification test.

^*Includes five individuals with positive SARS-CoV-2 NAAT before MIS-C illness, four with positive SARS-CoV-2 NAAT during MIS-C illness, and one with a positive SARS-CoV-2 NAAT before and during MIS-C illness.

^†Negative NAAT, negative anti-nucleocapsid antibody test, and positive anti-spike antibody test during MIS-C illness evaluation; these individuals did not have any reported positive NAAT results before MIS-C illness.